Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).

12 novembre 2026 aggiornato da: Merck Sharp & Dohme LLC

Uno studio multicentrico di fase 1b/2 etichetta aperta per valutare la sicurezza e l'efficacia di Raludotatug Deruxtecan con o senza altri agenti investigativi antitumo

Researchers are looking for other ways to treat high-grade serous and certain other ovarian cancer. High-grade means the cancer cells grow and spread quickly. Serous means the cancer started in the cells that cover the ovaries, the lining of the belly, or in the fallopian tubes.

Standard treatment (usual treatment) for people with high-grade serous ovarian cancer may include:

  • Chemotherapy, which is a treatment that uses medicine to destroy cancer cells or stop them from growing
  • Targeted therapy, which is a treatment that works to control how specific types of cancer cells grow and spread

Raludotatug deruxtecan (R-DXd) is a study treatment that is an antibody drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. Researchers want to know if R-DXd is safe to take with other treatments and if people tolerate them together. They also want to learn how many people have the cancer respond (gets smaller or goes away) to the treatments.

Panoramica dello studio

Descrizione dettagliata

This study has 2 parts: Part 1 is a dose escalation phase of R-DXd. Part 2 is the expansion phase and will use the Recommended Phase 2 Dose (RP2D) of R-DXd determined in Part 1.

Tipo di studio

Interventistico

Iscrizione (Stimato)

605

Fase

  • Fase 2
  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • Victoria
      • St Albans, Victoria, Australia, 3021
        • Reclutamento
        • Western Health-Sunshine & Footscray Hospitals ( Site 1002)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +61402775432
    • Ontario
      • Toronto, Ontario, Canada, M5G 2M9
        • Reclutamento
        • Princess Margaret Cancer Centre ( Site 0101)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 416-946-2818
    • Quebec
      • Montreal, Quebec, Canada, H4A 3J1
        • Reclutamento
        • McGill University Health Centre ( Site 0100)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 514-934-1934x31975
      • Montreal, Quebec, Canada, H2X 0A9
        • Reclutamento
        • Centre Hospitalier de l'Université de Montréal ( Site 0102)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 514-890-8000
      • Seoul, Corea del Sud, 03080
        • Reclutamento
        • Seoul National University Hospital ( Site 2000)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +82220723511
      • Seoul, Corea del Sud, 03722
        • Reclutamento
        • Severance Hospital, Yonsei University Health System ( Site 2002)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +82222282230
      • Seoul, Corea del Sud, 05505
        • Reclutamento
        • Asan Medical Center ( Site 2003)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +82230103646
      • Seoul, Corea del Sud, 06351
        • Reclutamento
        • Samsung Medical Center ( Site 2001)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 82234101382
    • Kyonggi-do
      • Goyang-si, Kyonggi-do, Corea del Sud, 10408
        • Reclutamento
        • National Cancer Center ( Site 2004)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 82319201760
      • Haifa, Israele, 3109601
        • Reclutamento
        • Rambam Health Care Campus ( Site 0202)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 972-4-7776234
      • Jerusalem, Israele, 9103102
        • Reclutamento
        • Shaare Zedek Medical Center ( Site 0201)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +972-(0)2-6555424
      • Petah Tikva, Israele, 4941492
        • Reclutamento
        • Rabin Medical Center ( Site 0203)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +97239378076
      • Ramat Gan, Israele, 5265601
        • Reclutamento
        • Sheba Medical Center ( Site 0200)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 972-3-5304498
      • Manchester, Regno Unito, M20 4BX
        • Reclutamento
        • The Christie NHS Foundation Trust ( Site 0405)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +441619187689
    • East Sussex
      • Brighton, East Sussex, Regno Unito, BN2 1ES
        • Reclutamento
        • University Hospitals Sussex NHS Foundation Trust ( Site 0404)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +44 01273 696 955
    • England
      • Fulham, England, Regno Unito, SW3 6JJ
        • Reclutamento
        • Royal Marsden Hospital ( Site 0402)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +442078118084
      • Sutton, England, Regno Unito, SM2 5PT
        • Reclutamento
        • The Royal Marsden NHS Foundation Trust. ( Site 0403)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +442078118084
    • London, City of
      • London, London, City of, Regno Unito, E1 1RD
        • Reclutamento
        • Barts Health NHS Trust ( Site 0401)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 020 7377 7000
      • London, London, City of, Regno Unito, SE1 3SS
        • Reclutamento
        • Guy s & St Thomas NHS Foundation Trust ( Site 0400)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +44 020 7188 7188
      • Barcelona, Spagna, 08035
        • Reclutamento
        • Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 0300)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +349325434528607
      • Madrid, Spagna, 28041
        • Reclutamento
        • Hospital Universitario 12 de Octubre ( Site 0304)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +34913908626
      • Madrid, Spagna, 28040
        • Reclutamento
        • Hospital Universitario Fundación Jiménez Díaz-START Madrid-FJD ( Site 0303)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 34915504800 x2805
      • Málaga, Spagna, 29010
        • Reclutamento
        • Hospital Universitario Virgen de la Victoria ( Site 0306)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +34951032508
    • Barcelona
      • L'Hospitalet de Llobregat, Barcelona, Spagna, 08908
        • Reclutamento
        • Institut Català d'Oncologia - L'Hospitalet ( Site 0302)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +34932607744
    • Madrid
      • Majadhonda, Madrid, Spagna, 28222
        • Reclutamento
        • HOSPITAL UNIVERSITARIO PUERTA DE HIERRO MAJADAHONDA ( Site 0307)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +34 911917358
    • Madrid, Comunidad de
      • Madrid, Madrid, Comunidad de, Spagna, 28027
        • Reclutamento
        • Clinica Universidad de Navarra ( Site 0301)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +349135319207513
    • Valenciana, Comunitat
      • Valencia, Valenciana, Comunitat, Spagna, 46014
        • Reclutamento
        • Hospital General Universitario de Valencia ( Site 0305)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +34 963187527
    • Connecticut
      • New Haven, Connecticut, Stati Uniti, 06510
        • Reclutamento
        • Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0019)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 203-785-2404
    • Kentucky
      • Louisville, Kentucky, Stati Uniti, 40202
        • Reclutamento
        • The University of Louisville, James Graham Brown Cancer Center ( Site 0009)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 502-562-3429
    • Louisiana
      • Shreveport, Louisiana, Stati Uniti, 71103
        • Reclutamento
        • TRIALS 365 ( Site 0020)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 318-408-1198
    • Massachusetts
      • Boston, Massachusetts, Stati Uniti, 02215
        • Reclutamento
        • Dana-Farber Cancer Institute ( Site 0015)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 877-338-7425
    • New York
      • New York, New York, Stati Uniti, 10065
        • Reclutamento
        • Memorial Sloan Kettering Cancer Center ( Site 0003)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 212-639-2000
    • Oklahoma
      • Oklahoma City, Oklahoma, Stati Uniti, 73104
        • Reclutamento
        • OU Health University of Oklahoma Medical Center ( Site 7000)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 405-271-1112
    • Texas
      • Fort Worth, Texas, Stati Uniti, 76104
        • Reclutamento
        • Texas Oncology - DFW ( Site 8000)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 615-329-7430
      • Houston, Texas, Stati Uniti, 77030
        • Completato
        • Houston Methodist Hospital ( Site 0010)
    • Utah
      • West Valley City, Utah, Stati Uniti, 84119
        • Reclutamento
        • START Mountain Region ( Site 0008)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 801-907-4750
    • Virginia
      • Charlottesville, Virginia, Stati Uniti, 22908
        • Reclutamento
        • University of Virginia Health System ( Site 0011)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 434-924-9333
      • Sankt Gallen, Svizzera, 9000
        • Reclutamento
        • HOCH Health Ostschweiz ( Site 0801)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +41714941111
    • Canton of Basel-City
      • Basel, Canton of Basel-City, Svizzera, 4031
        • Reclutamento
        • University Hospital Basel-Gynecology & Gynecologic Oncology ( Site 0802)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +41613284214
    • Canton of Vaud
      • Lausanne, Canton of Vaud, Svizzera, 1011
        • Reclutamento
        • CHUV (centre hospitalier universitaire vaudois) ( Site 0800)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +41795567362
      • Taipei, Taiwan, 100225
        • Reclutamento
        • National Taiwan University Hospital ( Site 3001)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +886223123456
      • Taoyuan, Taiwan, 33305
        • Reclutamento
        • Chang Gung Medical Foundation-Linkou Branch ( Site 3002)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +88633281200

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Femmina

Descrizione

Inclusion Criteria:

  • Has pathologically documented diagnosis of high-grade serous or high-grade endometrioid epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer
  • Participants in Part 1 cohorts and Part 2 Cohort A-2 Arms 1, 2, and 3, Cohort B-2, and Cohort C-2 Arm 3: Has measurable disease per Response Evaluation Criteria In Solid Tumors 1.1
  • Participants in Cohort A-1 Arms 2 and 3: Has relapsed disease after 1 to 3 prior lines of therapy and radiographic evidence of disease progression ≥6 months (≥180 days) after the last dose of platinum-based therapy (ie, platinum-sensitive disease)
  • Participants in Cohort B-1 and Cohort B-2: Has relapsed disease after 1 to 3 prior lines of therapy and radiographic evidence of disease progression <6 months (<180 days) after the last dose of platinum-based therapy (ie, platinum-resistant disease). Participants must have received no more than 1 prior bevacizumab-containing systemic treatment regimen
  • Participants in Cohort B-1, Cohort B-2, Cohort C-2 Arm 3, Cohort E-1 and if administering bevacizumab is planned in Cohort D or Cohort A-2 Arms 1, 2, or 3: Is a candidate for bevacizumab treatment
  • Has provided tumor tissue for biomarker research (all cohorts)
  • Has an Eastern Cooperative Oncology Group performance status of 0 to 1
  • Participants in Cohort C-1, Cohort C-2 Arm 3, Cohort D, and Cohort E-1: Has relapsed disease after 1 prior line of therapy, radiographic evidence of disease progression ≥6 months (≥180 days) after the last dose of platinum-based therapy (ie, platinum-sensitive disease) and progressed during prior treatment with poly-ADP ribose polymerase inhibitor (PARPi) in the first-line setting
  • Participants in Cohort A-2 Arms 1, 2, and 3: Has relapsed disease after 1 prior line of therapy and radiographic evidence of disease progression ≥6 months (≥180 days) after the last dose of platinum-based therapy (ie, platinum-sensitive disease)
  • Participants in Cohort C-2 Arms 1 and 2: Has a new, histologically confirmed diagnosis of International Federation of Gynecology and Obstetrics Stage III or Stage IV epithelial ovarian cancer (high-grade serous or high-grade endometrioid), fallopian tube cancer, or primary peritoneal cancer that is non-homologous recombination deficiency-positive
  • Participants in Cohort C-2 Arms 1 and 2: According to the investigator's assessment, PARPi first-line maintenance treatment for non- homologous recombination deficiency (HRD)-positive disease is not the preferred option for the participant
  • Participants in Cohort C-2 Arms 1 and 2: According to the investigator's assessment, bevacizumab treatment for non-HRD-positive disease is not the preferred option for the participant

Exclusion Criteria:

  • Has any of the following within 6 months before allocation/randomization: cerebrovascular accident, transient ischemic attack, or other arterial thromboembolic event
  • Has uncontrolled or significant cardiovascular disease
  • Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder, and any autoimmune, connective tissue, or inflammatory disorders with potential pulmonary involvement, or prior pneumonectomy
  • Has ≥Grade 2 peripheral neuropathy
  • Has received prior treatment with cadherin-6-targeted agents
  • Has received prior systemic anticancer therapy including investigational agents within 4 weeks or 5 half-lives (whichever is shorter) before allocation
  • Has received prior radiotherapy within 2 weeks of the start of study intervention, or has radiation-related toxicities, requiring corticosteroids
  • Receives chronic steroid treatment
  • Has known additional malignancy that is progressing or has required active treatment within the past 3 years
  • Has known active CNS metastases and/or carcinomatous meningitis
  • Has any history of interstitial lung disease (ILD)/pneumonitis irrespective of prior steroid use, current ILD, or suspected ILD, or ILD that cannot be ruled out by imaging at screening
  • Has active infection requiring systemic therapy
  • HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Non randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Cohort A-1 Arm 1 (R-DXd + Carboplatin Dose 1)

Participants receive escalating doses of intravenous (IV) raludotatug deruxtecan (R-DXd) in combination with carboplatin at Dose 1. Participants can receive up to a maximum of six 3-week cycles of carboplatin (approximately 4 months) and will receive raludotatug deruxtecan until disease progression or discontinuation.

IV infusion on Day 1 of every 3-week cycle.

Altri nomi:
  • MK-5909, R-DXD

IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.

Sperimentale: Cohort A-1 Arm 2 (R-DXd + Paclitaxel)

Participants receive escalating doses of IV R-DXd in combination with paclitaxel. Participants can receive up to a maximum of six 3-week cycles of paclitaxel (approximately 4 months) and will receive R-DXd until disease progression or discontinuation.

IV infusion on Day 1 of every 3-week cycle.

Altri nomi:
  • MK-5909, R-DXD

Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.

IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

Sperimentale: Cohort A-1 Arm 3 (R-DXd + Carboplatin Dose 2)

Participants receive escalating doses of intravenous (IV) R-DXd in combination with carboplatin at Dose 2. Participants can receive up to a maximum of six 3-week cycles of carboplatin (approximately 4 months) and will receive R-DXd until disease progression or discontinuation.

IV infusion on Day 1 of every 3-week cycle.

Altri nomi:
  • MK-5909, R-DXD

IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.

Sperimentale: Cohort B-1 (R-DXd + Bevacizumab)

Participants receive escalating doses of IV R-DXd in combination with bevacizumab until disease progression or discontinuation.

IV infusion on Day 1 of every 3-week cycle.

Altri nomi:
  • MK-5909, R-DXD

Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.

IV infusion on Day 1 of every 3-week cycle.

Altri nomi:
  • Include, in base all'approvvigionamento:
  • -Avastin®
  • -Alymsys®
  • -MVASI®
  • -Oyavas®
  • - Zirabev®
  • - Vegzelma®
  • -Aybintio®
  • -Breztri®
Sperimentale: Cohort B-2 (R-DXd RP2D + Bevacizumab)

Participants with platinum-resistant recurrent ovarian cancer (PRROC) receive recommended Phase 2 dose (RP2D) of IV R-DXd in combination with bevacizumab until disease progression or discontinuation.

IV infusion on Day 1 of every 3-week cycle.

Altri nomi:
  • MK-5909, R-DXD

Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.

IV infusion on Day 1 of every 3-week cycle.

Altri nomi:
  • Include, in base all'approvvigionamento:
  • -Avastin®
  • -Alymsys®
  • -MVASI®
  • -Oyavas®
  • - Zirabev®
  • - Vegzelma®
  • -Aybintio®
  • -Breztri®
Sperimentale: Cohort C-1 (R-DXd + Pembrolizumab)

Participants receive escalating doses of IV R-DXd in combination with pembrolizumab. Participants can receive up to a maximum of thirty-five 3-week cycles of pembrolizumab (approximately 2 years) and will receive R-DXd until disease progression or discontinuation.

IV infusion on Day 1 of every 3-week cycle.

Altri nomi:
  • MK-5909, R-DXD

Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.

IV infusion on Day 1 of every 3-week cycle for a maximum of 35 cycles.

Sperimentale: Cohort D (R-DXd +/- Bevacizumab)

Participants with platinum-sensitive recurrent ovarian cancer (PSROC) receive IV R-DXd in combination with or without bevacizumab until disease progression or discontinuation.

IV infusion on Day 1 of every 3-week cycle.

Altri nomi:
  • MK-5909, R-DXD

Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.

IV infusion on Day 1 of every 3-week cycle.

Altri nomi:
  • Include, in base all'approvvigionamento:
  • -Avastin®
  • -Alymsys®
  • -MVASI®
  • -Oyavas®
  • - Zirabev®
  • - Vegzelma®
  • -Aybintio®
  • -Breztri®
Sperimentale: Cohort A-2 Arm 1 (R-DXd RP2D + Carboplatin +/- Bevacizumab)

Participants with PSROC will receive the RP2D of R-DXd in combination with a maximum of 6 cycles of carboplatin with or without bevacizumab, until disease progression or discontinuation.

IV infusion on Day 1 of every 3-week cycle.

Altri nomi:
  • MK-5909, R-DXD

IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.

IV infusion on Day 1 of every 3-week cycle.

Altri nomi:
  • Include, in base all'approvvigionamento:
  • -Avastin®
  • -Alymsys®
  • -MVASI®
  • -Oyavas®
  • - Zirabev®
  • - Vegzelma®
  • -Aybintio®
  • -Breztri®
Sperimentale: Cohort A-2 Arm 2 (R-DXd RP2D + Paclitaxel +/- Bevacizumab)

Participants with PSROC will receive the RP2D of R-DXd in combination with a maximum of 6 cycles of paclitaxel with or without bevacizumab, until disease progression or discontinuation.

IV infusion on Day 1 of every 3-week cycle.

Altri nomi:
  • MK-5909, R-DXD

Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.

IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

IV infusion on Day 1 of every 3-week cycle.

Altri nomi:
  • Include, in base all'approvvigionamento:
  • -Avastin®
  • -Alymsys®
  • -MVASI®
  • -Oyavas®
  • - Zirabev®
  • - Vegzelma®
  • -Aybintio®
  • -Breztri®
Comparatore attivo: Cohort A-2 Arm 3 (Platinum-Based Doublet Chemotherapy +/- Bevacizumab)

Participants with PSROC will receive one of 3 regimens of investigator's choice of platinum-based doublet chemotherapy with or without bevacizumab. Platinum-based doublet chemotherapy will be administered for maximum of 8 cycles. Bevacizumab can be administered until disease progression or discontinuation.

IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

IV infusion on Day 1 of every 3-week cycle.

Altri nomi:
  • Include, in base all'approvvigionamento:
  • -Avastin®
  • -Alymsys®
  • -MVASI®
  • -Oyavas®
  • - Zirabev®
  • - Vegzelma®
  • -Aybintio®
  • -Breztri®

IV injection on days 1 and 8 of each 3-week Cycle

IV injection administered on Day 1 of each 4-week cycle

Altri nomi:
  • PLD
Sperimentale: Cohort E-1 (R-DXd + MK-2010)

Participants receive escalating doses of IV R-DXd in combination with MK-2010. Participants can receive up to a maximum of thirty-five 3-week cycles of MK-2010 (approximately 2 years) and will receive R-DXd until disease progression or discontinuation.

IV infusion on Day 1 of every 3-week cycle.

Altri nomi:
  • MK-5909, R-DXD

Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.

IV infusion on Day 1 of every 3-week cycle

Sperimentale: Cohort C-2 Arm 1 (Carboplatin + Paclitaxel + Pembrolizumab → R-DXd + Pembrolizumab)

Participants will receive carboplatin (Dose 1 or Dose 2), paclitaxel (five 3-week cycles), and pembrolizumab during the induction phase. During the maintenance phase, participants will receive RP2D of IV R-DXd (up to 2 years; participants with PR or SD at 2 years may continue until disease progression) in combination with pembrolizumab (up to thirty-five 3-week cycles).

IV infusion on Day 1 of every 3-week cycle.

Altri nomi:
  • MK-5909, R-DXD

IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

IV infusion on Day 1 of every 3-week cycle for a maximum of 35 cycles.

Sperimentale: Cohort C-2 Arm 2 (Carboplatin + Paclitaxel)

Participants will receive carboplatin (Dose 1 or Dose 2) and paclitaxel (seven 3-week cycles), followed by standard of care observation.

IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

Sperimentale: Cohort C-2 Arm 3 (R-DXd + Pembrolizumab + Bevacizumab)

Participants with PSROC will receive RP2D of R-DXd in combination with pembrolizumab (up to thirty-five 3-week cycles) and bevacizumab until progressive disease.

IV infusion on Day 1 of every 3-week cycle.

Altri nomi:
  • MK-5909, R-DXD

IV infusion on Day 1 of every 3-week cycle.

Altri nomi:
  • Include, in base all'approvvigionamento:
  • -Avastin®
  • -Alymsys®
  • -MVASI®
  • -Oyavas®
  • - Zirabev®
  • - Vegzelma®
  • -Aybintio®
  • -Breztri®

IV infusion on Day 1 of every 3-week cycle for a maximum of 35 cycles.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Part 1: Number of Participants Who Experience a Dose-limiting Toxicity (DLT) Per Common Terminology Criteria for Adverse Events, Version 5.0 (CTCAE v5.0)
Lasso di tempo: Up to 21 days

DLTs are defined as toxicities during the DLT evaluation period that are assessed by the investigator to be possibly, probably, or definitely related to study treatment and include: Grade 4 thrombocytopenia of any duration or Grade 3 thrombocytopenia lasting ≥7 days; Grade 3 or higher thrombocytopenia associated with clinically significant bleeding; Grade 4 lymphocytopenia lasting ≥14 days; Grade 4 anemia of any duration; any other Grade 4 hematologic toxicity lasting ≥7 days; febrile neutropenia Grade 3 or Grade 4 meeting pre-specifications; pre-specified hepatic organ toxicities; all Grade 3 or higher other nonhematologic toxicities except those pre-specified; other pre-specified nonhematologic toxicities; any delay in treatment with the planned dose of ≥21 days or discontinuation of treatment due to a toxicity during the DLT evaluation period, or Grade 5 toxicity. The number of participants with DLTs will be reported.

Up to 21 days
Part 1: Number of Participants with One or More Adverse Events (AEs)
Lasso di tempo: Up to approximately 3 years

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants with one or more AEs will be reported.

Up to approximately 3 years
Part 1: Number of Participants who Discontinue Study Intervention Due to an AE
Lasso di tempo: Up to approximately 3 years

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study intervention due to an AE will be reported.

Up to approximately 3 years
Part 2: Objective Response Rate (ORR)
Lasso di tempo: Up to approximately 3 years

ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1). The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR) will be presented.

Up to approximately 3 years
Part 2: Progression Free Survival (PFS) - Cohort C-2 Arm 1 and Arm 2
Lasso di tempo: Up to approximately 3 years

PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1). PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by blinded independent central review (BICR) will be presented.

Up to approximately 3 years

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Part 1: Objective Response Rate (ORR)
Lasso di tempo: Up to approximately 3 years

ORR is defined as the percentage of participants who have a confirmed Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumours version 1.1 (RECIST 1.1). ORR will be assessed by blinded independent central review (BICR).

Up to approximately 3 years
Part 2: Duration of Response (DOR)
Lasso di tempo: Up to approximately 3 years

For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1), DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR as assessed by Blinded Independent Central Review (BICR) will be presented.

Up to approximately 3 years
Part 2: PFS - Cohort A-2 Arm 2 and Arm 3
Lasso di tempo: Up to approximately 3 years

PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1). PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by blinded independent central review (BICR) will be presented.

Up to approximately 3 years
Part 2: Overall Survival (OS)
Lasso di tempo: Up to approximately 5 years

OS is defined as the time from the first dose of study treatment to death due to any cause.

Up to approximately 5 years
Part 2: Number of Participants with One or More AEs
Lasso di tempo: Up to approximately 3 years

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study intervention due to an AE will be reported.

Up to approximately 3 years
Part 2: Number of Participants who Discontinue Study Intervention Due to an AE
Lasso di tempo: Up to approximately 3 years

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study intervention due to an AE will be reported.

Up to approximately 3 years

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Collaboratori

Investigatori

  • Direttore dello studio: Medical Director, Merck Sharp & Dohme LLC

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

15 aprile 2025

Completamento primario (Stimato)

27 marzo 2029

Completamento dello studio (Stimato)

7 febbraio 2031

Date di iscrizione allo studio

Primo inviato

20 febbraio 2025

Primo inviato che soddisfa i criteri di controllo qualità

20 febbraio 2025

Primo Inserito (Effettivo)

25 febbraio 2025

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

13 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

12 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi